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V-ATPaseSuppression of oxidative phosphorylation combined with enhanced aerobic glycolysis and the resulting increased
generation of protons are common features of several types of cancer. An efﬁcient mechanism to escape cell death
resulting from intracellular acidiﬁcation is proton pump activation. In Ewing sarcoma (ES), although the
tumor-associated chimeric gene EWS-FLI1 is known to induce the accumulation of hypoxia-induced transcription
factor HIF-1α, derangements in metabolic pathways have been neglected so far as candidate pathogenetic mech-
anisms. In this paper, we observed that ES cells simultaneously activate mitochondrial respiration and high levels
of glycolysis. Moreover, although themost effective detoxiﬁcationmechanism of proton intracellular storage is ly-
sosomal compartmentalization, ES cells show a poorly represented lysosomal compartment, but a high sensitivity
to the anti-lysosomal agent baﬁlomycin A1, targeting the V-ATPase proton pump. We therefore investigated the
role of V-ATPase in the acidiﬁcation activity of ES cells. ES cells with the highest GAPDH and V-ATPase expression
also showed the highest acidiﬁcation rate.Moreover, the localization of V-ATPasewas both on the vacuolar and the
plasmamembrane of all ES cell lines. The acidic extracellular pH that we reproduced in vitro promoted high inva-
sion ability and clonogenic efﬁciency. Finally, targeting V-ATPase with siRNA and omeprazole treatments, we
obtained a signiﬁcant selective reduction of tumor cell number. In summary, glycolytic activity and activation of
V-ATPase are crucial mechanisms of survival of ES cells and can be considered as promising selective targets for
the treatment of this tumor.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Cancer cells survive and proliferate in competition with somatic cells
and according to the physical and biological properties of their microen-
vironment [1]. During cancer progression, as the tumormass increases in
size, neoplastic cells outgrow their blood supply and lack of adequate ac-
cess to oxygen and nutrients. It is well documented that tumors induce a
program of adaptive responses to thrive under hypoxic conditions by
switching their metabolism to upregulated glycolysis and by releasing
pro-angiogenic factors [2]. However, according to Otto Warburg's
ﬁndings [3], tumor cells may continue to metabolize carbon by the
glycolytic pathway even under adequate oxygen conditions. There-
fore, regardless of hypoxia [4], aerobic glycolysis is a constant featurellular pH; V-ATPase, vacuolar
at shock protein 60; GAPDHm,
xidative phosphorylation; BEC,
lomycin A1; OME, omeprazole
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rights reserved.in cancer development, as suggested by the high levels of glucose
consumption detected by positron emission tomography in most
malignancies [5]. The high, constant level of glycolytic activity of
tumor cells leads to an increased production of lactic acid that decreases
the pH of the extracellular microenvironment. Previous authors have
demonstrated that the extracellular pH (pHe) of different tumors is in
the range of 5.7–7.3 [6–8], whereas the pHe level of normal tissues is sig-
niﬁcantly more alkaline (7.2–7.5). The existence of an acidic intracellular
pH (pHi) is also indicated in vivo bymagnetic resonance spectroscopy [9].
Tomaintain pHhomeostasis and escape apoptosis induced by an increase
in proton concentration in the cytosol, cancer cells increase the activity
and/or expression of several pH regulators, resulting in the alkalinization
of pHi and acidiﬁcation of pHe [10]. Indeed, an increased expression and
activity of the transmembrane vacuolar (H+)-ATPase (V-ATPase) is a
constant feature of several tumor types, and its inhibition has been sug-
gested as a promising therapeutic target [11–14]. V-ATPase is an
ATP-driven proton pump that acidiﬁes the intracellular compartment
and transports protons across the plasmamembranes, both in physiolog-
ical processes and in human diseases [15]. V-ATPase is a large
multisubunit complex composed of a peripheral domain (V1), responsible
for hydrolysis of ATP, and an integral domain (V0) that carries out proton
transport [15]. In sarcoma cells, the survivalmechanismunder acidic con-
ditions and the activity of V-ATPase are still entirely unexplored.
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highlymalignant bone tumor developingmetastases in the vastmajority
of patients unlessmultiagent chemotherapy is applied [16]. ES is the sec-
ond most frequent bone tumor in childhood and adolescence, and is
characterized by the presence of EWS–ETS gene rearrangements [17].
Recently, some authors have reported that, in ES, hypoxia enhances the
malignant phenotype through an upregulation of the EWS–FLI1 fusion
gene by hypoxia-inducible factor (HIF)-1α [18]. HIF-1α and HIF-1β are
themainmediators of the hypoxic response that favors cell proliferation
through the control of the expression of numerous genes that regulate
glucose uptake, metabolic reprogramming from oxidative phosphoryla-
tion (OXPHOS) to glycolysis, and lactic acid production [19,20]. Interest-
ingly, glycogen granules accumulate in normal or cancer cells in a
HIF-1-dependent manner [21], and the positive glycogen reaction to
the cytochemical periodic acid-Schiff (PAS) stain is an additional feature
that is currently used for the diagnosis of ES in parallel to the molecular
detection of the EWS-FLI1 fusion gene [22].
In this study, we endorsed V-ATPase as a survival mechanism of ES
cells under acidic conditions, and as a promising selective therapeutic
target to be considered for future trials.
2. Material and methods
2.1. Cell lines
A-673, SK-N-MC, RD-ES, SK-ES-1 ES cell lines were purchased
from the American Type Culture Collection (ATCC, Manassas, VA),
and cultured in RPMI (Sigma, Manassas, VA) buffered at 7.4 pH plus
20 units/mL penicillin, 100 μg/mL streptomycin (Gibco, Life Technolo-
gies, Paisley, UK), 10% fetal bovine serum FCS (FCS, Euroclone, Milan,
Italy) (completemedium). Normal human ﬁbroblasts (hFG)were isolat-
ed from the gingiva of healthy donors. Tissue explants were cultured in
complete medium [23]. All the cell cultures were incubated at 37 °C in
a humidiﬁed 5% CO2 atmosphere. In the different assays complete
medium was also used at different pH (5.8 or 6.5). The speciﬁc pH in
the culture medium was maintained by using different concentrations
of sodium bicarbonate needed for the preset pH in 5% CO2 atmosphere,
according to the Henderson–Hasselbach equation. At the end-point of
each experiment, the ﬁnal pH in the supernatant was always measured
to ascertain the maintenance of the pH value along the incubation
time. For all assays but the bone invasion assay, cells were cultured on
human ﬁbronectin (Gibco, Life Technologies).
2.2. Western blotting
Western blotting was carried out to detect ATP synthase subunit
α, Complex II subunit 30 kDa, Complex III subunit Core 2, heat
shock protein 60 (HSP60), glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), V0c and V1B2 subunits of the V-ATPase protein, and actin in
total lysates. Cells were maintained in complete medium and lysated
at semi-conﬂuence with RIPA buffer [Tris pH 7.6 50 mM, NaCl
150 mM, Triton-X 100 5%, sodium deoxycholate 0.25%, EGTA pH 8
1 mM, NaF 1 mM] (Sigma) supplemented with protease inhibitors
(Roche, Milan, Italy). Equal amounts of protein lysates were subjected
to reducing SDS-PAGE on a polyacrylamide gel, transferred to nitrocel-
lulose membranes, and subjected to immunoblot analysis. Blots were
probed with MitoProﬁle Total OXPHOS human antibody Cocktail
1:300 (Abcam, Cambridge, UK), or with an anti-GAPDH (1:2000, Santa
Cruz Biotechnology, Dallas, TX), anti-HSP60 (1:2000, Sigma), anti-V1B2
V-ATPase (1:200, Sigma), anti-V0c V-ATPase (1:50, Abcam), anti-actin
(1:1000, Cell Signaling, Danvers, MA) polyclonal antibodies. Incubation
with horseradish peroxidase-conjugated anti-rabbit, anti-mouse (GE
Healthcare, Buckinghamshire, UK), or anti-goat antibodies (Santa Cruz
Biotechnology, Dallas, TX) followed. To detect different antigens within
the same blot, nitrocellulose membranes were stripped with Restore
Western Blot Stripping buffer (Thermo Fisher Scientiﬁc, Rockford, IL),and then reprobed. The reaction was revealed by a chemiluminescence
substrate (ECL Western Blotting Detection Reagents, GE Healthcare,
Chalfont St. Giles, Buckinghamshire, UK). Immunoblot assays were
repeated ﬁve times for the BEC index assay and three times for all the
other assays. Signal fromeach bandwas quantiﬁed by dedicated software
for densitometric evaluation (Quantity One, Biorad Laboratories Head-
quarters, Hercules, CA).2.3. Mitochondrial activity
To stain mitochondria, rhodamine-based MitoTracker Orange
CMTMRos (Molecular Probes, Life Technologies) was used. MitoTracker
stains live mitochondria with an intact membrane potential. Brieﬂy,
cells were incubated with MitoTracker diluted in serum free RPMI to a
ﬁnal concentration of 250 nM for 10–15 min at 37 °C. Then, cells
were ﬁxed with 3% paraformaldehyde and 300 mM sucrose (Sigma)
in PBS. Analysis of labeled cells was performed using a confocal micro-
scope (Nikon D-Eclipse C-1, Tokyo, Japan).2.4. Immunoﬂuorescence
For the immunoﬂuorescence staining with an antibody against the
surface of intact mitochondria, cells were washed with PBS, ﬁxed in 3%
paraformaldehyde in PBS containing 300 mM sucrose for 20 min at
22 °C. After washing in PBS, permeabilization was performed with 0.1%
Triton X-100 for 5 min. Then, cells were incubated with the MAB1273
antibody 1:100 (Millipore, Billerica, MA), and subsequently with
anti-mouse Alexa green 488 nm (Molecular Probes, Life Technologies),
and observed by confocal microscopy. For the co-localization analysis
of LC3B or V-ATPase V0a1 with lysosomes, before washing and ﬁxation,
living cells were incubated with Lysotraker (0.25 μM, Molecular Probes,
Life Technologies) in complete medium for 30 min at 37 °C. After the
incubation with the primary antibody (anti-V-ATPase V0a1 antibodies
1:30, Sigma, and anti-LC3B antibody 1:50, Cell Signaling), and secondary
anti-mouse antibodyAlexa green 488 nm(1:1000,Molecular Probes, Life
Technologies), nuclei were stained with Hoechst 33258 (1.25 μg/ml
Sigma). Cells were then analyzed by a confocal microscope (Nikon
TI-E). For the co-localization analysis of V-ATPase V0a1 with plasma
membrane, cells were washed and ﬁxed as described above, but not
permeabilized. After the immunoﬂuorescence stain for the ATPase V0a1,
cells were also stained with a Fluorescent Cell Linker Dye (PKH26,
Sigma) with long aliphatic tails that bind lipid regions of the cell
membrane.2.5. Lysosome staining
Living adherent cells at low conﬂuence and maintained in com-
plete medium were treated with 0.37% neutral red (Sigma) for 2 h
at 37 °C and 5% CO2, washed with PBS, and observed. Alternatively,
for ﬂuorescence experiments, cells were incubated with 1 μg/ml acri-
dine orange dye (Sigma) for 10 min at room temperature in complete
medium in the dark, and rinsed with PBS prior to ﬂuorescence mi-
croscopy analysis.2.6. Electron microscopy
For ultrastructural evaluation, pellets of ES cells were ﬁxed in 2.5%
glutaraldehyde in 0.1 M cacodylate buffer (Sigma), pH 7.4, for 1 h at
RT, postﬁxed with 1% osmium tetroxide (Sigma), dehydrated in a
graded series of ethanol, and embedded in Epon. Thin sections were
stained with uranyl acetate and lead citrate, and observed with a
transmission electron microscope (Zeiss, Milan, Italy).
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a) Indirect assay: Cellswere seeded in 96-well plates (10,000 cells/well
for hFG and 50,000 cells/well for ES cells) in complete medium. After
24 h, the medium was changed with complete medium at pH 6.5 or
pH 7.4, added or not with baﬁlomycin A1 (BF-1) 2–5–10 nM (Sigma),
or with omeprazole (OME) 60–120–210 μM (Sigma). After additional
72 h, the cell number was evaluated by an acid phosphatase assay, as
previously described [24]. Brieﬂy, the culture medium was removed
and each well was washed once with PBS, and added with 100 μl of
buffer containing 0.1 M sodium acetate (pH 5.0), 0.1% Triton X-100,
and 5 mM p-nitrophenil phosphate. The plate was placed in a 37 °C in-
cubator for 3 h. The reactionwas stoppedwith the addition of 10 μl of a
1 N NaOH, and color development was assayed at 405 nm using a
microplate reader (Tecan Inﬁnite F200pro, Männedorf, Switzerland);
b) Direct assay: Cells were seeded in 6-well plates (50,000 cells/well
for hFG and 150,000 cells/well for ES cells) in complete medium. After
24 h, the medium was changed with new complete medium at pH 6.5
added or not with BF-1 10 nM (Sigma), or OME 120 and 210 μMFig. 1. Ewing sarcoma bioenergetic signature. The ES cell lines were studied for mitochondri
pared to normal human ﬁbroblasts (hFG). (A) Upper panel: Western blot analysis of the ATP
GAPDH. Lower panel: densitometric analysis of Western blot (n = 3, *P b 0.05). The Ratio A
drial mass analyzed by immunoﬂuorescence using an anti-mitochondria surface-FITC antibo
Representative overlayered images of 35 xy ﬁelds of 0.5 μm distance, scale bar 10 μm. ES c(Sigma). Cell growth was evaluated after additional 72 h by the direct
counting of cells using erythrosine dye (Sigma). The experiments
were repeated three times, and with two replicate for each assay.2.8. Extracellular pH measurement
Cells were seeded into 75 cm2 ﬂasks (133,000 cells/cm2). As a
control, ﬂasks with medium alone were also set. After 24 h at 37 °C in
a humidiﬁed 5% CO2 atmosphere, when cells reached the semi-
conﬂuence, ﬂasks with or without cells were washed twice with PBS,
and supplemented with 10 ml of RPMI without sodium bicarbonate,
andwith 0.1% FCS. The ﬂasks were sealed in order to avoid gas exchange
with the external microenvironment. After additional 24 h, ﬂasks were
opened, themedium collected, and the pH promptly measured by a dig-
ital pH-meter (pH 301, HANNA Instruments,Milan, Italy). The difference
of the pH value of the collected medium vs control was reported as pHe
decrement. The experimentwas repeated three times,with two replicate
for each assay.al and glycolytic activity by analyzing the BEC index and Mytotraker staining, and com-
synthase subunit α, Complex II subunit 30 kDa, Complex III subunit Core 2, HSP60, and
TP synthase subunit/alpha/HSP60/GAPDH was referred as the BEC index. (B) Mitochon-
dy and (C) MytoTracker Orange CMTMRos staining, observed by confocal microscope.
ells have both higher mitochondrial and glycolytic activity.
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In order to assess if acidic pHe (6.5) can induce apoptosis, ES cells
were seeded on glass slides at low density and in complete medium.Fig. 2. Lysosome compartment of Ewing sarcoma cells. (A) Neutral red and (B) Acridine ora
ment. Scale bar 10 μm. (C) Ultrastructural morphology. Black arrows, lysosomes. Represent
staining (red) of A-673 cells. Nuclei are counterstained with Hoechst 333258 (blue). R
co-localization of LC3B and lysosome staining. Scale bar 20 μm. ES cells have a lower numbAfter 24 h, the medium was changed with complete medium at pH 6.5,
or 7.4 with or without staurosporine (100 μM, Sigma) as a positive
control. After 4 days, cells were ﬁxed and permeabilized as described
above, and incubated for 30 min with Hoechst 33258 (2.25 μg/ml,nge staining, representative images. Red staining is associated with lysosome compart-
ative images, scale bar 1.5 μm. (D). LC3B immunoﬂuorescence (green) and Lysotracker
epresentative image of an xy ﬁeld acquired by confocal microscope. White arrows,
er of lysosomes when compared to hFG.
1109S. Avnet et al. / Biochimica et Biophysica Acta 1832 (2013) 1105–1116Sigma). The percentage of cells with apoptotic bodies out of a total of 100
cells, and in 3 differentﬁelds, was counted using an epiﬂuorescentmicro-
scope. The experiment was repeated three times.
2.10. Cell cycle analysis
In order to analyze cell cycle distribution after exposure to acidic con-
ditions, DNA content and bromodeoxyuridine (BrdU) incorporation
were determinedby simultaneous analysis of propidium iodide andﬂuo-
rescein isothiocyanate (FITC)-conjugated anti-BrdU ﬂuorescence. Cells
were seeded at low density in completemedium, and after 24 h theme-
dium was changed with complete medium at pH 6.5 or 7.4. After addi-
tional 48 h, cells were incubated with 10 mM BrdU (Sigma) for 60 min
before harvesting. Cells were collected by trypsinization, followed by
ﬁxation in 40% ethanol for 20 min. Partial DNA denaturation was
performed by incubating cells in HCl, followed by neutralization with
sodium tetraborate. Samples were then exposed to a monoclonal
anti-BrdU FITC antibody (BD Biosciences, Erembodegem, Belgium),
washed, and ﬁnally stained with 2.5 mg/ml propidium iodide (Sigma).
Flow cytometric analysis was performed with a Coulter EPICS1 XL Flow
Cytometer (Coulter Corporation, Beckman Coulter, Milan, Italy).
Monoparametric and biparametric analyses were performed using the
WinMDI 2.7 software. The experiment was repeated three times.
2.11. Invasion assays
a) Gelatin quenching: metalloproteinase activity was quantiﬁed
by seeding ES cells in complete medium in 24 well plates
(350,000 cells/well). After 24 h, medium was changed with complete
medium at pH 5.8–6.5–7.4. After additional 48 h, cells were washed
once with PBS, and incubated at 37 °C with 500 μl of PBS for 1 h. PBS
was then collected, centrifuged and the supernatantwas used for the gel-
atin quenching assay. Adherent cells were lysated with RIPA buffer with
protease inhibitors as previously described. Equal amounts of proteinsFig. 3. Effect of baﬁlomycin A1 on cell number of Ewing sarcoma. (A) Acid phosphatase indir
pH after 72 h. Percentage of inhibition with respect to untreated cells at the respective pH
cells treated with BF-1 (10 nM) at pH 6.5 with respect to untreated cells (mean ± SE, n =
acidic condition, whereas hFG were completely unaffected.from the supernatant were added to 100 μl of gelatin quenching (DQ™
Gelatin, Invitrogen, Life Technologies) in a 96 well plate. After 24 h at
37 °C, the ﬂuorescence emission was measured by a microplate reader.
Results from samples were subtracted by results obtained with the acel-
lular condition, and normalized by dividing for the total protein content
in the cell lysates. The experiments was performed in duplicate and re-
peated three times. b) Bone invasion: to measure the bone resorption
ability, ES cells were seeded (10,000) onto 96-well plates coated with
europium-conjugated Type I collagen (Osteolyse Assay Kit, Cambrex,
East Rutherford, NJ) in completemedium, and incubated at 37 °C in a hu-
midiﬁed 5%CO2 atmosphere.Wellswithmediumwithout cellswere also
set. After one day, the medium was changed at different pH (6.5 or 7.4).
After 2 days of culture, supernatants were transferred into new wells
containing the ﬂuorophore releasing reagent. Fluorescence emission
was determined by a time-resolved plate reader (Wallac Victor; Perkin
Elmer, Waltham, MA). The RFU values of the supernatant from different
ES cultures were then subtracted with supernatant from acellular wells
with the medium at the respective pH.
2.12. Clonogenic assay
Clonogenic efﬁciencywas determined by seeding ES cells at low den-
sity (280 cells in 60 mmdiameter Petri dishes) in completemedium, and
incubated at 37 °C in a humidiﬁed 5% CO2 atmosphere. After 24 h,
medium was changed with complete medium at different pH (6.5 or
7.4). Colonies were ﬁxed with methanol, stained with crystal violet,
and counted after 6–7 days. The experiment was repeated four times,
with two replicate for each assay.
2.13. Real-time PCR
Total RNA was extracted from semi-conﬂuent cells using the RNeasy
MiniKit (Qiagen,Hilden, Germany). TotalmRNAwas reverse transcribed
by Advantage RT-for-PCR Kit (Roche). The expression of V-ATPase V0cect assay of cells treated at different concentration of baﬁlomycin A1 (BF-1) at different
(mean ± SE, n = 4, *P b 0.05). (B) Percentages of inhibition at 72 h of the number of
4, *P b 0.05). BF-1 signiﬁcantly impaired ES cell number and with more efﬁcacy under
1110 S. Avnet et al. / Biochimica et Biophysica Acta 1832 (2013) 1105–1116(NM_001694.2) was evaluated by Real Time PCR by using a Light Cycler
instrumentation (Roche), by amplifying 1 μg of cDNA and the Universal
Probe Library System (Roche). Probes and primers were selected using
a web-based assay design software (ProbeFinder https://www.roche-applied-science.com). V-ATPase V0c-f 5′-TTCGTTTTTCGCCGTCAT-3′;
V-ATPase V0c-r 5′-CCACTGGGATGATGGACTTC-3′. The protocol of ampli-
ﬁcation was: 95 °C for 10 min; 95 °C for 10 s, 60 °C for 30 s, and 72 °C
for 1 s for 45 cycles; 40 °C for 30 s. Results were expressed as the ratio
1111S. Avnet et al. / Biochimica et Biophysica Acta 1832 (2013) 1105–1116between V0c subunit and β-actin as a reference gene (NM_001101.2;
ACTB-f 5′-CCAACCGCGAGAAGATGA-3′; ACTB-r 5′-CCAGAGGCGTACA
GGGATAG-3′) according to the 2−ΔΔCT method [25]. The experiment
was repeated two times, with two replicates for each assay.2.14. siRNA transfection
Speciﬁc gene silencing effect was obtained by siRNA technology
associated with pipette-type electroporation. SK-N-MC and A-673
cells were trypsinized at semi-conﬂuence, and counted after erythro-
sine dye staining. 15 μL of cell suspension containing 300,000 cells
and 2 pmol of speciﬁc siRNA (ON-TARGETplus Human ATP6V0C
siRNA Smart poll, Dharmacon, Thermo Scientiﬁc, Waltham, MA) or
control siRNA (siRNA ctr, ON-TARGETplus Non-targeting Control
Pool, Dharmacon) were transferred into a 1-mm cuvette (Neon®
Transfection System, Invitrogen, Life Technologies). Electroporated
cells were transferred into 2 mL of complete medium, and seeded in
12-well plates (30,000 cells/well) for RNA isolation and cell counting or
in a plate of 10 cm of diameter for protein extraction (600,000 cells).
After one day (T0), medium was changed with complete medium at
pH 6.5. At T0 and after additional 3 days (T1) cells were counted by
using erythrosine dye. At T1, cells were also used to isolate RNA and
protein, as previously described. Both assays were repeated three times
in duplicate.2.15. Statistical analysis
Statistics was performed with the StatViewTM 5.0.1 software (SAS
Institute, Cary, NC). Due to the low number of observations, data were
considered as not normally distributed, and nonparametric tests were
used. The Mann-Whitney U test was used for the difference between
groups. In all statistical calculations, data were expressed as mean ±SE,
and differences were considered signiﬁcant at P values ≤ 0.05.3. Results
3.1. Glycolytic metabolism in Ewing sarcoma cells
The glycolytic activity and the mitochondrial respiration of ES cells
were evaluated in comparison with that of hFG by Western blot
analysis, to deﬁne the bioenergetic cellular (BEC) index, and by
MytoTracker staining. The BEC index (β-F1-ATPase/HSP60/GAPDH
ratio) describes the bioenergetic activity of mitochondria relative to
the glycolytic potential of the cell [26,27]. In comparison to hFG, ES
cells showed a signiﬁcantly higher mitochondrial activity and an
increased glycolytic activity (Fig. 1A). The MitoTracker staining
co-localizes with cytochrome c [28], and enters only into mitochon-
dria with a normal membrane potential and function. MitoTracker
staining is therefore an indirect marker of OXPHOS of healthy and
functional mitochondria. By using both MitoTracker and FITC staining
with an antibody against an antigen of intact mitochondrial surface,
we conﬁrmed the presence of a high number of active mitochondria
in ES cells (Fig. 1B and C). In conclusion, ES cells showed a higher
glycolytic activity, although associated with a higher OXPHOS, as
compared to hFG.Fig. 4. V-ATPase expression and localization in Ewing sarcoma cells. (A) Western blotting o
tometric analysis (lower panel, mean ± SE, n = 3, *P b 0.05 vs SK-N-MC). (B) Immunoﬂ
Lysotraker (red) by confocal microscope analysis. Nuclei were counterstained with Hoechst
sentative images of an xy ﬁeld, scale bar 20 μm. (C) Immunoﬂuorescence of the transmemb
membrane dye (PKE26, red) by confocal microscope analysis. Representative overlayered im
ages. Z-sections of one chosen scanned XY-section are also shown in the lower panel (XZ-
unbuffered medium was measured with respect to acellular condition (mean ± SE, n =
cells and localized also at the cell membrane. SK-N-MC cells showed the highest expression3.2. Lysosomes in Ewing sarcoma cells
To evaluate if the higher glycolytic activity of ES cells correspond to
an increase in lysosome number, we used neutral red and acridine or-
ange staining. In comparison to normal hFG, ES cells showed a lower
number of lysosomes (Fig. 2A andB), as also conﬁrmed byultrastructural
analysis (Fig. 2C). By electronmicroscopy, lysosomes of ES cells appeared
to be either multivesicular bodies or secondary lysosomes (data not
shown). Part of the observed lysosomes were autolysosomes, as sug-
gested by the positive immunostaining with the autophagy-associated
LC3B antigen (Fig. 2D).
To evaluate the role of the lysosomal compartment in ES cells under
acidic conditions, we used an indirect assay with increasing concentra-
tions of the anti-lysosomal BF-1 agent at acidic (pH 6.5) versus alkaline
standard conditions (pH 7.4). We observed a dose-dependent and sig-
niﬁcant inhibition of ES cell survival that was further enhanced under
acidic conditions (Fig. 3A). Conversely, even the highest concentrations
of BF1 were completely ineffective in hFG, either at acidic or alkaline
conditions (Fig. 3A). Results obtained in acidic medium were also con-
ﬁrmed by direct cell counting (Fig. 3B). From our results we can assume
that, although ES cells show a low number of lysosomes, the anti-
lysosome BF1 agent is very effective and selective to impair tumor sur-
vival under acidic conditions.
3.3. V-ATPase expression and localization in Ewing sarcoma cells
Since V-ATPase is a key effector of proton secretion and lysosome
activity, we analyzed V-ATPase expression and localization in ES cells.
The presence of V-ATPase in the cell lysate was veriﬁed by using an
antibody against the V0c and V1B2 subunits in Western blotting anal-
ysis (Fig. 4A). In particular, we choose the V0c as it has been success-
fully targeted by siRNA strategies also in other cancers [13,29,30], and
since it is the target of BF-1 [31]. V-ATPase is formed by two different
domains, the V1 domain and the intramembrane V0 domain, that can
be reversibly dissociated [15], and the expression pattern of a subunit
of the Vc domain should be similar to the expression pattern of a
subunit of the V1 domain. The analysis of V1B2 subunit is a further
validation of results obtained on V0c subunit. All ES cells expressed
the V0c and V1B2 subunits, and the SK-N-MC cell line at a signiﬁcantly
higher extent. For the immunoﬂuorescence assay, we used an anti-
body that can stain also non permeabilized cells and recognizes
the V0a1 transmembrane domain. In permeabilized cells, the V0a1
subunit is localized in the Golgi apparatus in the perinuclear region
and in some vesicles and is partially co-localized with lysosome spe-
ciﬁc staining (Fig. 4B). Adversely, in ES cells with an intact membrane,
V-ATPase co-localized with a cell membrane dye (Fig. 4C). Notably,
we also found that the ES cell line with the highest expression of
V-ATPase, SK-N-MC, also showed the highest acidiﬁcation activity
(Fig. 4D). In summary, in ES cells the V-ATPase is localized in the
Golgi apparatus, at the lysosomal compartment, and on the plasma-
lemma. The most acidifying ES cells also show the highest levels of
V-ATPase expression.
3.4. Effects of acidic pHe on Ewing sarcoma cells
As a consequence of a high glycolytic activity, acidiﬁcation of themi-
croenvironment can stronglymodulate key aspects of tumor biology. Byf V0c and V1B2 subunits of V-ATPase (representative images, upper panel), and densi-
uorescence of V-ATPase V0a1 subunit (green) in permeabilized cells incubated with
333258 (blue). White arrows, co-localization of V-ATPase V0a1 and Lysotraker. Repre-
rane V-ATPase V0a1 subunit (green) in not permeabilized cells stained with a cytosolic
ages of 35 xy ﬁelds of 0.5 μm distance, scale bar 10 μm, merge and green emission im-
section). White arrows, co-localization. (D) Acidiﬁcation activity. pH decrement of the
6, 0.01 b *P b 0.05, 0.005 b **P ≤ 0.01 vs SK-N-MC). V-ATPase is expressed in all ES
of V-ATPase and the highest acidiﬁcation rate.
1112 S. Avnet et al. / Biochimica et Biophysica Acta 1832 (2013) 1105–1116maintaining ES cells at an acidic pHe (6.5)we observed that the number
of cells was reduced (Fig. 5A), although the number of apoptotic cells
was unaffected (Fig. 5B). The lower number of cells at pH 6.5 is possibly
a consequence of an increase in the G0-G1 phase of the cell cycle,Fig. 5. Effect of acidic pHe on Ewing sarcoma cell number, invasion, and clonogenic efﬁcie
(B) Percentage of apoptotic cells at different pHe. Treatment with staurosporine (100 μM
with anti-BrdU antibody and cytoﬂuorimetric analysis at different pH (mean ± SE, n = 3
pH. Results are reported as the percentage of ﬂuorescence emission with respect to acel
cells at different pHe, measured by Osteolyse assay kit (mean ± SE, n = 3, *P b 0.05). (E)
panel, representative images for SK-N-MC cells; right panel, mean ± SE, n = 8, 0.01 b *P b
rate but a higher is invasion ability and clonogenic efﬁciency.combined with a decrease of the S phase, as observed in all ES cell
lines (Fig. 5C) but RD-ES cells (Fig. 5A). Likewise, the metalloproteinase
activity (Fig. 5D) and bone collagen degradation (Fig. 5E) were signiﬁ-
cantly improved at acidic conditions for almost all the ES cell lines, asncy. (A) No. of cells at different pHe at 72 h (mean ± SE, n = 4, *P b 0.05 vs pH 7.4).
) was used as positive control (mean ± SE, n = 3, *P b 0.05). (C) Cell cycle analysis
, *P b 0.05 vs pH 7.4). (C) Gelatin degradation activity of cell supernatant at different
lular supernatant (mean ± SE, n = 3, *P b 0.05). (D) Type I collagen degradation of
Number of colonies formed under different pHe of ES cells seeded at low density (left
0.05, 0.005 b **P ≤ 0.01, ****P b 0.001). At acidic pHe ES cells showed a lower growth
1113S. Avnet et al. / Biochimica et Biophysica Acta 1832 (2013) 1105–1116compared to the pHe 7.4 condition. Interestingly, the acidic microenvi-
ronment also signiﬁcantly increased the clonogenic efﬁciency of ES cells
(Fig. 5F). We can therefore postulate that, although the acidic microen-
vironment decreases the proliferation rate of ES cells, it prompts tumor
cell to a more aggressive phenotype.Fig. 6. Effect of V-ATPase blockage on cell growth of Ewing sarcoma. (A) Upper panel, grap
siRNA against the V-ATPase V0c subunit. Results are reported as the percentage of expres
panel, western blot analysis of the protein expression of V-ATPase V0c subunit in ele
electroporated with the V-ATPase V0c siRNA and maintained at 6.5 pH over time (T1 = 72
with omeprazole at different pH and at different concentrations, after 72 h. Results are repo
(mean ± SE, n = 4, 0.01 b *P b 0.05, 0.005 b **P ≤ 0.01). (D) Percentages of inhibition at
spect to untreated cells (mean ± SE, n = 4, *P b 0.05 vs untreated cells). Omeprazole at
siRNA, or omeprazole were signiﬁcantly effective to inhibit ES cell number. Omeprazole sign
as hFG were completely unaffected.3.5. Effect of V-ATPase inhibition on tumor growth of Ewing sarcoma
First, we demonstrated the speciﬁc and signiﬁcant inhibition of
mRNA and protein expression in SK-N-MC and A-673 cells treated
with a siRNA against the V0c subunit of V-ATPase (Fig. 6A). Afterwards,h representation of mRNA analysis of SK-N-MC and A-673 cells electroporated with a
sion in respect with the not treated condition (mean ± SE, n = 3, *P b 0.05). Lower
ctroporated cells, representative images. (B) Number of SK-N-MC and A-673 cells
h) (mean ± SE, n = 6, *P b 0.05 ). (C) Acid phosphatase indirect assay of cells treated
rted as the percentage of inhibition with respect to untreated cells at the respective pH
72 h of the number of cells treated with omeprazole (120–210 μM) at pH 6.5 with re-
210 μM was also signiﬁcantly more effective than 120 μM (#P b 0.05). Either speciﬁc
iﬁcantly impaired ES cell number and with more efﬁcacy under acidic condition, where-
1114 S. Avnet et al. / Biochimica et Biophysica Acta 1832 (2013) 1105–1116we showed that treatment with V-ATPase V0c siRNA signiﬁcantly
decreased the number of cells of both SK-N-MC and A-673 cells at
acidic pHe (pHe 6.5, Fig. 6B, 57.6 ± 4.9% of inhibition for SK-N-MC
P = 0.0209, and 55.2 ± 7.0% for A-673 P = 0.0339 vs no siRNA).
Similarly, by using an indirect assay, we obtained a strong inhibition
of cell number for all the ES cells treated both at acidic (pH 6.5) and
alkaline (pH 7.4) conditions with the highest dose of the speciﬁc
anti-V-ATPase agent OME (Fig. 6C). Notably, the inhibition induced by
OME was signiﬁcant also at the lowest concentration, but only at
pH 6.5, in all ES cells, with the exception of the RD-ES cell line that
also had a low V-ATPase expression (Fig. 4A). Adversely, OME was
completely ineffective in hFG (Fig. 6C). Results obtained with OME
were further validated by direct cell counting (Fig. 6D). Also in this
case, we observed a dose-dependent effect. The most susceptible cell
line was SK-N-MC. In summary, inhibition of V-ATPase is dependent
on the level of expression of the V-ATPase protein and is an effective
strategy to impair ES survival under acidic conditions.
4. Discussion
The role ofmitochondria in cancer development and progression is a
fundamental and complex issue [32,33]. SinceWarburg's theory [3], it is
nowwidely accepted that tumor cells drive a metabolic shift character-
ized by the suppression of OXPHOS combined with the activation of
glycolysis as the main pathway for ATP synthesis [34]. In this study,
we veriﬁed this metabolic alteration in ES, an extremely aggressive,
poorly differentiated cancer of putativemesenchymal origin. According
to the bioenergetic signature (BEC index) [26,27], and to the staining
with the Mytotraker dye, we found that ES cells have a signiﬁcantly
higher mitochondrial activity with respect to normal ﬁbroblasts. ES
cells also showed a higher GAPDH expression, with particular regard
to the SK-N-MC cells, reﬂecting a higher glycolytic activity. In keeping
with the in vitro high glucose consumption of ES cells, the sensitivity,
speciﬁcity, and accuracy of FDG-PET in this tumor have relevant impacts
on treatment [35]. Using this approach, we therefore concluded that ES
cells develop a compensatory response to adverse local environment
that facilitates tumor progression through the simultaneous activation
of mitochondrial respiration and upregulation of glycolysis. This is in
contrast with the classical Warburg theory, in which the complete loss
of function of mitochondria in cancer is postulated. The role of mito-
chondria in cancer is still controversial, however, and inmany instances
tumor cells have been demonstrated to carry fully functional mitochon-
dria [36], possibly due to the ability of cancer cells to recycle these
organelles [37].
Interestingly, several ES cell lines are null for p53, possibly because
the EWS-FLI1 chimeric protein can directly and indirectly interfere
with p53 activity [38,39]. The inhibition, loss and/or mutation of p53,
one of the most common events in tumorigenesis, results in a decreased
oxygen consumption and increased glycolysis [40,41], also by enhancing
HIF-1α levels [42]. As a conﬁrmation, Knowles et al. demonstrated that
ES cell lines express HIF-1α [43]. In turn, HIF-1αmay induce EWS-FLI1
expression in a time-dependent manner [18,19]. Notably, A-673 and
SK-N-MC show higher levels of HIF1α activation when compared to
RD-ES and SK-ES-1 cell lines [43]. An excessive glycolytic activity in tu-
mors can also be a consequence of microenvironmental alterations. In
fact, cancer cells are induced to produce large amounts of metabolic
acid generated by glycolysis, glucose utilization, and lactate production.
To prevent acidity-induced apoptosis, tumor cells are forced to enhance
proton efﬂux, leading to a signiﬁcant decrease of pH in the extracellular
environment [6–9]. On the other side, both human and animal tumor
cells have a slightly alkaline pHi (pH 7.1-7.2) [44,45], suggesting that,
despite lower than normal levels of pHe, cancer cells are capable to effec-
tively reduce the excess of protons in the cytoplasm by active transport
across theplasmamembrane and storagewithin the lysosomal compart-
ment. Lysosomes and lysosome-related organelles constitute a system of
acidic compartments that interconnect the inside of the cell with theextracellular space via secretory and endocytic pathways. We veriﬁed
the extension of the lysosomal compartment and activity in ES cells,
and compared ES cells with hFG. In this paper, we used a primary culture
of human ﬁbroblasts as a control, also with the aim to demonstrate the
selectiveness and effectiveness of the suggested targeting in the ES
cells with respect to normal cells. Lysosomes and lysosome-related or-
ganelles were rather scanty in all ES cell lines, in sharp contrast to hFG.
The observed presence of autolysosomes in ES cells further supports
the hypothesis of a survival mechanism under acidic stress, as already
demonstrated in other cancers [46]. In fact, even if ES cells have only a
few lysosomes, the cytotoxic effect of autophagy inhibitor baﬁlomycin
A1 is very high, especially under acidic conditions. Of note, BF-1 treat-
ment was completely ineffective in normal human cells, also at pH 6.5.
Although the level of speciﬁcity is still controversial, the main target of
BF-1 is the proton pump V-ATPase. Thus, we wondered if V-ATPase
could represent an effective target for the treatment of ES. V-ATPase is
themajor electrogenic pumpof vacuolarmembranes, and is crucial to es-
tablish andmaintain intracellular pH gradients across specialized organ-
elle membranes, including the trans-Golgi network, secretory granules,
endosomes, and lysosomes [47]. V-ATPase has recently gained great at-
tention in cancer, especially with regard to its role in microenvironment
acidiﬁcation and in metastasis [10,47]. Interestingly, among the many
mechanisms that regulate the tumor microenvironment, V-ATPases are
especially valuable because they can be blocked by proton pump inhibi-
tors [48,49]. First, we looked at the V-ATPase expression and localization.
V-ATPase was constantly expressed in ES cells and at the highest level
both for V0c and V1B2 subunits in SK-N-MC, the ES cell line with the
highest GAPDH expression and with the highest susceptibility to the
BF-1 treatment. Notably, the signal for V-ATPase in ES cells was localized
inside the cell and on the cell membrane. The membrane expression of
V-ATPase is possibly due to improper sorting of normal cellular compo-
nents and was proven to be functional also in other tumors [10]. Immu-
nohistochemical analysis in breast cancer cells has revealed a higher
plasmalemmal V-ATPase in highlymetastatic cells compared to lowmet-
astatic cells [50,51]. Accordingly, our data suggest that V-ATPase on the
membrane of ES cells is an additional factor that possibly contributes to
the formation of metastases [52]. V-ATPase is usually recycled from the
plasma membrane for the formation of endosomes that fuse with vesi-
cles with hydrolytic enzymes derived from the Golgi apparatus to gener-
ate new lysosomes. Accordingly, in non permeabilized cells, we also
observed the presence of V-ATPase localization in clusters closed to the
plasma membrane and possibly associated with the invagination of the
membrane to form endosomes. In agreement with results obtained
with the level of expression of V-ATPase, we found the highest acidiﬁca-
tion rate in SK-N-MC cells. Based on our ﬁndings, glycolytic ES cells have
a strong proton secretion activity that contribute to form an acidicmicro-
environment and that is directly related to V-ATPase expression. The low
pHe has been repeatedly implicated as playing a key role both in cell
transformation and in the active progression and maintenance of the
neoplastic process [48]. We then veriﬁed the consequence of the acidiﬁ-
cation activity exerted by the V-ATPase activity in ES cells. Adachi and
Tannock induced intratumoral acidiﬁcation in an in vivo cancer model
by using the vasodilating drug captopril, and simultaneously obtained a
signiﬁcant delay in tumor growth [53]. Consistent with these in vivo
data, we found that under acidic (6.5) in vitro pH conditions, the number
of ES cells is signiﬁcantly decreased. However, the number of apoptotic
cell is not affected whereas the percentage of cells in G0–G1 phase is in-
creased. Thus, the reduction in cell number is a consequence of a delay of
the cell cycle rather than of a cytotoxic effect of the acidic pHe. On the
other hand, the ability to degrade gelatin and bone collagen and the
clonogenic efﬁciency is signiﬁcantly increased. An increased invasion
ability under acidic conditions is a well-known feature of tumor cells
that is due to an increase of matrix metalloproteinase [48,54]. In ES, the
observed collagen and gelatin degradation is possibly a consequence of
the secretion of MMP-9 [55–57]. In this tumor, the increased invasive
capacity and the enhanced cloning efﬁciency has been previously
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to the acidiﬁcation of tumormicroenvironment. Consequently, in ES cells
the ability to survive and to invade the surrounding tissues under acidic
conditions is increased, possibly through the activation of V-ATPase.
In an effort to consider V-ATPase as a candidate therapeutic target for
ES, we focused on the inhibitory effect of this proton pump on tumor
growth. First, to directly correlate the cell number inhibition with im-
pairment of V-ATPase expressionwe used amore speciﬁc targeting tech-
nique than BF-1 treatment. siRNA silencing strongly affected V0c mRNA
expression and resulted in a signiﬁcant reduction of the number of ES
cells. We chose the V0c subunit because its inhibition was very effective
to impair growth and chemoresistance also in other tumors [13,29].
Moreover, the V0c subunit is the target of the V-ATPase inhibitor BF-1
[58] that already showed to be effective in ES cells, as described above.
Secondly, we used OME which is known to block V-ATPase through the
binding to the V1A subunit [59]. Among the different proton transport-
er/ion inhibitors, OME and other related drugs have sparked great inter-
est in cancer [48,60]. Two important attractive features of these agents
are that they require acidic conditions to be converted into the active
form, thus providing the possibility of tumor-speciﬁc selection, and
that their use in long-term therapy produces only limited side effects
[61]. Proton pump inhibitors have been previously used in sarcoma
and bone tumor patients at low dosage, and only to prevent gastric
lesions as a side effect of the treatment with conventional drugs. There-
fore, proton pump inhibitors have been never described and published
in sarcomas as an anti-cancer therapy. We obtained a signiﬁcant reduc-
tion of the number of cells that survived under low pHe with either
siRNA, or OME. Moreover, we observed a dose-dependent effect of OME
treatment.
In summary, in this study we focused on the consequences of
the metabolic alterations of ES. We demonstrated that activation of
V-ATPase is a necessary survival mechanism in an acidic microenviron-
ment and that V-ATPase should be considered as a promising therapeutic
target.
5. Conclusions
The peculiar metabolic derangements, including the acidiﬁcation of
extracellular microenvironment, have not been considered so far as a
basis for novel therapeutic targets in ES. In this study, we demonstrate
that ES cells strongly acidify the medium and can survive under acidic
pHe through the activity of a plasmalemmal V-ATPase. Moreover, we
also show that the survival of ES can be effectively impaired by
anti-V-ATPase strategies. In conclusion, although results from this study
warrant further investigations also in an in vivo model of this cancer,
this paper endorses the use of anti-V-ATPase agents, such as proton-
pump inhibitors, for the treatment of ES.
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